Product Review,AAGIGILTV (residues 27–35

The MART-1 peptide sequence is a critical area of study, particularly within the field of melanoma research. MART-1, also known as Melanoma Antigen Recognized by T cells 1 or Melan-A, is a protein that plays a significant role as a tumor-associated melanocytic differentiation antigen. This antigen is expressed in melanocytes and in a high percentage (80-95%) of melanoma tumors, making it a prime target for the immune system and for therapeutic interventions. Understanding the specific sequences of MART-1 peptides is crucial for developing effective immunotherapies.

The Significance of MART-1 Peptide Sequences

The MART-1 gene is a substantial genetic element, measuring 18 kb long and comprising five exons. The protein itself is a transmembrane protein consisting of 118 amino acids with a single transmembrane domain. The immunogenicity of MART-1 is largely attributed to specific peptide fragments derived from this protein. These fragments can be recognized by T-cells, initiating an immune response against melanoma cells.

One of the most extensively studied MART-1 peptide sequences is the nonamer peptide derived from MART-1 amino acids 27-35. This sequence, typically represented as AAGIGILTV, is a naturally presented epitope. Another significant fragment is MART-1 peptide (26-35), which can be represented as ELAGIGILTV or EAAGIGILTV, depending on the starting amino acid. These peptides, particularly those that bind to the HLA-A*0201 allele, are of great interest. The Peptide sequence: H-ELAGIGILTV-OH is a common representation used in research.

Variations and Analogs of MART-1 Peptides

Research into MART-1 peptide sequences has led to the identification of various analogs and modified peptides. For instance, the [Leu28]MART-1(27-35) derived peptides incorporate a beta-amino acid substitution. Furthermore, the [Leu27]-Melan-A, MART-1 (26-35) analog, with the sequence ELAGIGILTV, has demonstrated superior HLA-A*0201 binding properties and immunogenicity compared to the natural Melan-A sequence. This suggests that subtle modifications to the peptide sequence can significantly enhance its effectiveness as an immunotherapeutic target.

The study of T-cell receptor (TCR) usage in response to these peptides, such as the T-cell receptor repertoire in matched MART-1 peptide-stimulated T-cells, helps to elucidate the mechanisms of anti-tumor immunity. Researchers often synthesize a range of peptides, including 15-mer peptides with 11-amino acid overlap covering the complete sequence of MART-1, to comprehensively map the antigenic landscape.

Applications in Melanoma Immunotherapy

The MART-1 peptide is a pivotal target in melanoma immunology. MART-1 Antigen is recognized as a tumor-associated antigen, and vaccination with these Mart 1 antigen sequences aims to boost the body's own immune response against the tumor. The MART-1 [27-35] sequence is a common immunogenic epitope for HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs).

The development of MART-1 peptides for therapeutic purposes involves rigorous scientific investigation. For example, the 15-mer amino acid sequence 101-115 PPAYEKLSAEQSPPP has been identified as a B cell epitope. Researchers also explore the use of synthetic signal sequences to enhance the presentation of these epitopes.

The availability of various MART-1 peptides for research purposes, such as MART-1 Peptides and PepTivator Melan-A/MART-1, human, facilitates advancements in understanding and treating melanoma. These products often come with detailed specifications, including purity levels (e.g., >90% by HPLC/MS) and delivery formats (e.g., freeze-dried in plastic vials). The ability to study specific sequences, like ELAGIGILTV, and their interactions with immune cells and HLA molecules is fundamental to designing effective cancer vaccines and cell therapies. In essence, the precise MART-1 peptide sequence is a key to unlocking robust anti-melanoma immune responses.